Vyant Bio (VYNT) 10-Q 16 May 22 2022 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2022	May 10, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2022
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	001-35817
Entity Registrant Name	VYANT BIO, INC.
Entity Central Index Key	0001349929
Entity Tax Identification Number	04-3462475
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	2 Executive Campus
Entity Address, Address Line Two	2370 State Route 70
Entity Address, Address Line Three	Suite 310
Entity Address, City or Town	Cherry Hill
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	08002
City Area Code	(201)
Local Phone Number	479-1357
Title of 12(b) Security	Common Stock, $0.0001 Par Value
Trading Symbol	VYNT
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		29,412,798

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 16,440	$ 20,608
Trade accounts and other receivables	585	434
Inventory	497	475
Prepaid expenses and other current assets	1,941	895
Assets of discontinuing operations – current	1,001	802
Total current assets	20,464	23,214
Non-current assets:
Fixed assets, net	908	1,020
Operating lease right-of-use assets, net	1,764	673
Long-term prepaid expenses and other assets	1,265	1,221
Assets of discontinuing operations – non-current	8,128	11,508
Total non-current assets	12,065	14,422
Total assets	32,529	37,636
Current liabilities:
Accounts payable	1,765	740
Accrued expenses	1,476	764
Deferred revenue	72	74
Obligations under operating leases, current portion	241	174
Obligation under finance lease, current portion	158	157
Liabilities of discontinuing operations – current	3,760	3,522
Total current liabilities	7,472	5,431
Obligations under operating leases, less current portion	1,540	516
Obligations under finance leases, less current portion	258	293
Long-term debt	57	57
Liabilities of discontinuing operations – non-current	834	49
Total liabilities	10,161	6,346
Commitments and contingencies
Stockholders’ equity:
Preferred stock, authorized 9,764 shares $0.0001 par value, none issued
Common stock, authorized 100,000 shares, $0.0001 par value, 29,412 and 28,993 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively	3	3
Additional paid-in capital	110,411	110,174
Accumulated deficit	(87,976)	(78,813)
Accumulated comprehensive loss	(70)	(74)
Total Stockholders’ equity	22,368	31,290
Total liabilities and Stockholders’ equity	$ 32,529	$ 37,636

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares shares in Thousands	Mar. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Preferred stock, shares authorized	9,764	9,764
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares issued	0	0
Common stock, shares authorized	100,000	100,000
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares issued	29,412	28,993
Common stock, shares outstanding	29,412	28,993

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenue:
Total revenue	$ 303	$ 203
Operating costs and expenses:
Research and development	1,551	820
Selling, general and administrative	2,763	1,214
Merger related costs		2,145
Total operating costs and expenses	4,700	4,639
Loss from operations	(4,397)	(4,436)
Other (expense) income:
Change in fair value of warrant liability		214
Change in fair value of share-settlement obligation derivative		(250)
Loss on debt conversions		(2,518)
Interest expense	(9)	(368)
Total other expense	(9)	(2,922)
Loss from continuing operations before income taxes	(4,406)	(7,358)
Income tax expense (benefit)
Loss from continuing operations	(4,406)	(7,358)
Discontinuing operations (net of $0 tax benefit in 2022 and 2021)	(4,757)	(8)
Net loss	(9,163)	(7,366)
Cumulative translation adjustment	4
Comprehensive loss	$ (9,159)	$ (7,366)
Net loss per share attributed to common stock – basic and diluted:
Net loss per share from continuing operations	$ (0.15)	$ (2.31)
Net loss per share from discontinuing operations	(0.17)
Net loss per share	$ (0.32)	$ (2.31)
Weighted average shares outstanding:
Weighted average common shares outstanding - Basic and Diluted	29,012,536	3,184,106
Service [Member]
Revenue:
Total revenue	$ 94	$ 97
Operating costs and expenses:
Cost of goods sold	38	64
Product [Member]
Revenue:
Total revenue	209	106
Operating costs and expenses:
Cost of goods sold	$ 348	$ 396

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parenthetical) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Income Statement [Abstract]
Income tax expense (benefit)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Temporary Equity Common Stockholders' Equity (Deficit) (Unaudited) - USD ($) $ in Thousands	Preferred Stock [Member]Series A Preferred Stock [Member]	Preferred Stock [Member]Series B Preferred Stock [Member]	Preferred Stock [Member]Series C Preferred Stock [Member]	Temporary Equity [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Beginning balance at Dec. 31, 2020	$ 12,356	$ 16,651		$ 29,007		$ 1,514	$ (37,954)		$ (36,440)
Beginning balance, shares at Dec. 31, 2020	4,612,000	3,489,000			2,594,000
Stock-based compensation						366			366
Exercise of stock options						4			$ 4
Exercise of stock options, shares									29,916
Issuance of Incremental shares to StemoniX shareholders upon Merger
Issuance of Incremental shares to StemoniX shareholders upon Merger, shares					805,000
Net loss							(7,366)		(7,366)
Issuance of Series C Convertible Preferred shares, net of issuance costs of $214			$ 1,786	1,786
Issuance of Series C Convertible Preferred shares, net of issuance costs of $214, shares			567,000
Issuance of Common Stock for acquisition consideration					$ 2	59,918			59,920
Issuance of Common Stock for acquisition consideration, shares					11,007,000
Conversion of Preferred Stock to Common Stock upon Merger	$ (12,356)	$ (16,651)	$ (1,786)	(30,793)	$ 1	30,792			30,793
Conversion of preferred stock to common stock upon merger, shares	(4,612,000)	(3,489,000)	(567,000)		11,197,000
Conversion of 2020 Notes to Common Stock upon Merger						16,190			16,190
Conversion of 2020 convertible notes to common sock upon merger, shares					3,339,000
Preferred stock warrant settled for Common Stock upon Merger
Preferred stock warrant settled for Common Stock upon Merger , shares					43,000
Warrant liability reclassified to equity upon Merger						421			421
Ending balance at Mar. 31, 2021					$ 3	109,205	(45,320)		63,888
Ending balance, shares at Mar. 31, 2021					28,985,000
Beginning balance at Dec. 31, 2021					$ 3	110,174	(78,813)	$ (74)	31,290
Beginning balance, shares at Dec. 31, 2021					28,993,000
Stock-based compensation						334			334
Exercise of stock options						4			$ 4
Exercise of stock options, shares					5,000				5,174
Vesting of restricted stock
Vesting of restricted stock, shares					8,000
Issuance of Incremental shares to StemoniX shareholders upon Merger						(101)			(101)
Issuance of Incremental shares to StemoniX shareholders upon Merger, shares					406,000
Foreign currency translation adjustment								4	4
Net loss							(9,163)		(9,163)
Ending balance at Mar. 31, 2022					$ 3	$ 110,411	$ (87,976)	$ (70)	$ 22,368
Ending balance, shares at Mar. 31, 2022					29,412,000

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Temporary Equity Common Stockholders' Equity (Deficit) (Unaudited) (Parenthetical) $ in Thousands	3 Months Ended
	Mar. 31, 2021USD ($)
Series C Preferred Stock [Member]
Payments of stock issuance costs	$ 214

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash Flows from Operating Activities:
Net loss	$ (9,163)	$ (7,366)
Net loss from discontinuing operations	4,757	8
Reconciliation of net loss to net cash used in operating activities, continuing operations:
Stock-based compensation	278	366
Amortization of operating lease right-of-use assets	98	117
Depreciation and amortization expense	142	126
Change in fair value of share-settlement obligation derivative		250
Change in fair value of warrant liability		(214)
Change in fair value of 2020 Convertible Note with fair value election		4
Accretion of debt discount		173
Loss on conversion of debt		2,518
Changes in operating assets and liabilities net of impacts of business combination:
Trade accounts and other receivables	(151)	138
Inventory	(22)	6
Prepaid expenses and other current assets	213	(110)
Accounts payable	(279)	(727)
Obligations under operating leases	(98)	(117)
Accrued expenses and other current liabilities	714	251
Net cash used in operating activities, continuing operations	(3,511)	(4,577)
Net cash used in operating activities, discontinuing operations	(461)	(8)
Net cash used in operating activities	(3,972)	(4,585)
Cash Flows from Investing Activities:
Equipment purchases	(30)	(26)
Cash acquired from acquisition		30,163
Net cash (used in) provided by investing activities, continuing operations	(30)	30,137
Net cash used in investing activities, discontinuing operations	(30)
Net cash (used in) provided by investing activities	(60)	30,137
Cash Flows from Financing Activities:
Issuance of common stock, net of issuance costs	(97)	4
Issuance of Series C Preferred Stock, net of issuance costs		1,786
2020 Convertible Note proceeds		5,022
Principal payments on long-term debt		(82)
Principal payments on obligations under finance leases	(34)
Net cash (used in) provided by financing activities, continuing operations	(131)	6,730
Net cash used in financing activities, discontinuing operations	(5)
Net cash (used in) provided by financing activities	(136)	6,730
Net (decrease) increase in cash and cash equivalents	(4,168)	32,282
Cash and cash equivalents, and restricted cash beginning of the period	20,608	792
Cash and cash equivalents, and restricted cash end of the period	16,440	33,074
Cash and cash equivalents	16,440	32,337
Restricted cash		737
Total cash and cash equivalents and restricted cash	16,440	33,074
Supplemental disclosure of cash flow information from continuing operations:
Cash paid for interest	7
Cash paid for income taxes	1
Non-cash investing activities from continuing operations:
Fair value of non-cash merger consideration		59,920
Right-of-use asset obtained in exchange for new lease	1,189
Non-cash financing activities from continuing operations:
Conversion of Preferred Stock to Common Stock upon Merger		30,793
Conversion of 2020 Convertible Notes and Accrued Interest to Common Stock upon Merger		16,190
Reclass warrant liability to equity upon Merger		$ 421

Organization and Description of

Organization and Description of Business	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Description of Business	Note 1. Organization and Description of Business Vyant Bio, Inc. (the “Company”, “Vyant Bio”, “VYNT” or “we”) , As further described in Note 3, i n December 2021, the Company’s Board of Directors approved a plan to sell the vivo vivo vivo The accompanying unaudited condensed consolidated financial statements include all accounts and wholly-owned subsidiaries and have been prepared in accordance with accounting principles generally accepted in the U.S. (“GAAP”). All intercompany transactions have been eliminated. In accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”), the Company has omitted footnote disclosures that would substantially duplicate the disclosures contained in the audited consolidated financial statements of the Company. No new accounting pronouncement issued or effective has had, or is expected to have, a material impact on the Company’s condensed consolidated financial statements. These unaudited condensed consolidated financial statements should be read together with the audited consolidated financial statements for the year ended December 31, 2021, and notes thereto included in our Annual Report on Form 10-K as filed with the SEC. The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Ultimate results could differ from those estimates. The results of operations for the three months ended March 31, 2022 are not necessarily indicative of the results that may be expected for the entire 2022 year. Dollar amounts in tables are stated in thousands of U.S. dollars.

Cancer Genetics, Inc. Merger

Cancer Genetics, Inc. Merger	3 Months Ended
	Mar. 31, 2022
Business Combination and Asset Acquisition [Abstract]
Cancer Genetics, Inc. Merger	Note 2. Cancer Genetics, Inc. Merger The Company formerly known as Cancer Genetics, Inc. (“CGI”), StemoniX and CGI Acquisition, Inc. (“Merger Sub”) entered into a merger agreement on August 21, 2020, which was amended on February 8, 2021 and February 26, 2021 (as amended, the “Merger Agreement”). Pursuant to the terms of the Merger Agreement, Merger Sub was merged (the “Merger”) with and into StemoniX on March 30, 2021, with StemoniX surviving the Merger as a wholly owned subsidiary of the Company. For U.S. federal income tax purposes, the Merger qualified as a tax-free “reorganization”. Concurrent with the Merger closing, the Company changed its name to Vyant Bio, Inc. Under the terms of the Merger Agreement, upon consummation of the Merger, the Company issued (i) an aggregate of 17,977,544 0.0001 891,780 0.66 4.61 1.46 143,890 5.9059 The Merger was accounted for as a reverse acquisition with StemoniX being the accounting acquirer of CGI using the acquisition method of accounting. Under acquisition accounting, the assets and liabilities (including executory contracts, commitments and other obligations) of CGI, as of March 30, 2021, the closing date of the Merger, were recorded at their respective fair values and added to those of StemoniX. Any excess of purchase price consideration over the fair values of the identifiable net assets is recorded as goodwill. The total consideration paid by StemoniX in the Merger amounted to $ 59.9 11,007,186 50.74 2,157,686 9.04 55,907 139 804,711 The Company incurred $ 2.145 63 The following details the allocation of the preliminary purchase price consideration recorded on March 30, 2021, the acquisition date, with adjustments recorded through March 30, 2022, the end of the period for which purchase accounting adjustments can be recorded, and the final purchase price allocation. Schedule of Preliminary Allocation of the Purchase Price Consideration Preliminary Adjustments Final Assets acquired: Cash and equivalents $ 30,163 $ - $ 30,163 Accounts receivable 705 - 705 Other current assets 806 227 1,033 Intangible assets 9,500 - 9,500 Fixed assets 416 (256 ) 160 Goodwill 22,164 216 22,380 Long-term prepaid expenses and other assets 1,381 - 1,381 Total assets acquired $ 65,135 $ 187 $ 65,322 Liabilities assumed: Accounts payable and accrued expenses $ 2,670 $ 437 $ 3,107 Current liabilities of discontinuing operations 588 (141 ) 447 Obligations under operating leases 198 - 198 Obligations under finance leases 106 - 106 Deferred revenue 1,293 (114 ) 1,179 Payroll and income taxes payable 360 5 365 Total liabilities assumed $ 5,215 $ 187 $ 5,402 Net assets acquired: $ 59,920 $ - $ 59,920 The Company has completed valuation analyses necessary to assess the fair values of the tangible and intangible assets acquired and liabilities assumed and the amount of goodwill to be recognized as of the acquisition date. Fair values were based on management’s estimates and assumptions. The Company recognized intangible assets related to the Merger, which consist of the tradename valued at $ 1.5 million with an estimated useful life of ten years and customer relationships valued at $ 8.0 million with an estimated useful life of ten years. The initial measurement of these intangible assets were classified as Level 3 measurements within the fair value hierarchy. The value of the vivo 1.0 % royalty rate was appropriate given the business-to-business nature of the vivo vivo Key assumptions in this analysis included an estimated 10% annual customer attrition rate based on historical vivoPharm operations, a blended U.S. federal, state and Australian income tax rate of 27.1%, a present value factor of 8.5% as well as revenue, cost of revenue and operating expense assumptions regarding the future growth, operating expenses, including corporate overhead charges, and required capital investments . The following presents the unaudited pro forma combined financial information as if the Merger had occurred as of January 1, 2020: Schedule of Proforma Financial Information March 31, 2021 Total revenue $ 1,841 Net loss $ (6,495 ) Pro forma loss per common share, basic and diluted $ (.21 ) Pro forma weighted average number of common shares outstanding, basic and diluted 28,985 The pro forma combined results of operations are not necessarily indicative of the results of operations that actually would have occurred had the Merger been completed as of January 1, 2020, nor are they necessarily indicative of future consolidated results.

Discontinuing Operations

Discontinuing Operations	3 Months Ended
	Mar. 31, 2022
Discontinued Operations and Disposal Groups [Abstract]
Discontinuing Operations	Note 3. Discontinuing Operations I n December 2021, the Company’s Board of Directors approved a plan to sell the vivo vivo vivo The Company classified the vivo vivo vivo 20.2 million. The Company valued the vivo vivo 4.3 million during the quarter ended March 31, 2022 consisting of the write-off of the remaining $ 2.2 million goodwill balance and reducing the cost basis of customer relationships and tradenames by $ 1.8 million and $ 0.3 million, respectively. Also included in discontinuing operations are pre-Merger-related payables related to Cancer Genetic’s sale of its BioPharma and Clinical businesses (“Pre-Merger discontinuing operations”). As of March 31, 2022 and December 31, 2021, $ 409 The following tables reflect the vivo vivo Results of discontinuing operations were as follows for the three months ended March 31, 2022: Schedule of Discontinuing Operations from Income Statement and Balance Sheet Revenue $ 1,353 Cost of goods sold 775 General and administrative 1,045 Impairment of goodwill and intangible assets 4,290 Total operating costs and expenses 6,110 Loss from discontinuing operations (4,757 ) Total other income - Loss from discontinuing operations before income taxes (4,757 ) Income tax benefit - Net loss from discontinuing operations $ (4,757 ) Asset and liabilities of discontinuing operations were as follows as of March 31, 2022 and December 31, 2021: March 31, December 31, 2021 Accounts receivable $ 542 $ 457 Other current assets 459 345 Assets of discontinuing operations - current 1,001 802 Fixed assets, net of accumulated depreciation 191 163 Operating lease right-of-use assets 941 30 Intangible assets, net 6,634 8,787 Goodwill - 2,164 Other assets 362 364 Assets of discontinuing operations - non-current 8,128 11,508 Accounts payable $ 442 $ 358 Accrued expense 417 418 Obligation under operating lease, current 151 29 Obligation under finance lease, current 34 32 Deferred revenue 1,942 1,911 Taxes payable 365 365 Other current liabilities 409 409 Liabilities of discontinued operations - current 3,760 3,522 Obligations under operating leases, less current 794 2 Obligations under finance leases, less current 40 47 Liabilities of discontinued operations - non-current 834 49 During the three months ended March 31, 2022, the vivoPharm business signed an extension to its Hershey, Pennsylvania facility lease and a new lease in South Australia resulting in an increase of $ 1.0 Intangible assets consisted of the following as of March 31, 2022 and December 31, 2021: Schedule of Intangible Assets March 31, 2022 December 31, 2021 Customer relationships $ 6,187 $ 8,000 Trade name 1,160 1,500 Intangible assets, net 7,347 9,500 Less accumulated amortization (713 ) (713 ) Intangible assets, net $ 6,634 $ 8,787 Goodwill arising from the Merger was solely attributed to the vivo Schedule of Goodwill Rollforward 2022 Beginning balance, January 1 $ 2,164 Purchase price adjustments - Impairment charge (2,164 ) Ending balance, March 31 $ -

Inventory

Inventory	3 Months Ended
	Mar. 31, 2022
Inventory Disclosure [Abstract]
Inventory	Note 4. Inventory The Company’s inventory consists of the following: Schedule of Inventory March 31, December 31, 2021 Finished goods $ 56 $ 23 Work in process 51 138 Raw materials 390 314 Total inventory $ 497 $ 475

Fixed Assets

Fixed Assets	3 Months Ended
	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Fixed Assets	Note 5. Fixed Assets Presented in the table below are the major classes of fixed assets by category: Schedule of Fixed Assets March 31, December 31, 2021 Equipment $ 2,752 $ 2,733 Furniture and fixtures 6 6 Leasehold improvements 261 251 Fixed assets, gross 3,019 2,990 Less accumulated depreciation (2,111 ) (1,970 Total $ 908 $ 1,020 Depreciation expense from continuing operations recognized during the three months ended March 31, 2022 and 2021 was $ 142 126

Leases

Leases	3 Months Ended
	Mar. 31, 2022
Leases
Leases	Note 6. Leases The Company leases its laboratory, research and administrative office space under various operating leases. In January 2022, the Company recorded a $ 1.2 The components of operating and finance lease expenses for the three-month periods ended March 31, are as follows: Components of Lease Expense and Supplemental Information 2022 2021 Operating lease costs $ 98 $ 107 Finance lease costs: Depreciation of ROU assets 40 - Interest on lease liabilities 7 - Total finance lease cost 47 - Variable lease costs - - Short-term lease costs - - Total lease cost $ 145 $ 107 Amounts reported in the condensed consolidated balance sheets as of March 31, 2022 and December 31, 2021 are as follows: Schedule of Amounts Reported in the Consolidated Balance Sheet 2022 2021 Operating leases: Operating lease ROU assets, net $ 1,764 $ 673 Operating lease current liabilities 241 174 Operating lease long-term liabilities 1,540 516 Total operating lease liabilities 1,781 690 Finance leases: Equipment 477 477 Accumulated depreciation (79 ) (63 ) Finance leases, net 398 414 Current installment obligations under finance leases 158 157 Long-term portion of obligations under finance leases 258 293 Total finance lease liabilities $ 416 $ 450 Other information related to leases from continuing operations for the three-month periods ended March 31, are as follows: 2022 2021 Supplemental cash flow information: Cash paid for amounts included in the measurement of lease liabilities: Operating cash flow from operating leases $ 98 $ 117 Financing cash flow from finance leases 34 - Weighted average remaining lease term: Operating leases 5.18 5.65 Finance leases 2.5 - Weighted average discount rate: Operating leases 8.3 % 9.6 % Finance leases 6.5 % 8.1 % Annual payments of lease liabilities under noncancelable leases from continuing operations as of March 31, 2022 are as follows: Schedule of Annual Payments of Lease Liabilities Under Noncancelable Leases Operating leases Finance leases Remainder of 2022 $ 303 $ 136 2023 433 181 2024 423 136 2025 427 - 2026 441 - 2027 200 - Thereafter - - Total undiscounted lease payments 2,227 452 Less: Imputed interest (446 ) (36 ) Total lease liabilities $ 1,781 $ 416

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Note 7. Income Taxes The Company recognizes deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets include, among others, capitalized research and development costs, net operating loss carryforwards and research and development tax credit carryforwards. Deferred tax assets are partially offset by deferred tax liabilities arising from intangibles, fixed assets and lease assets. Realization of net deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain based on the Company’s history of losses. Accordingly, the Company’s net deferred tax assets have been fully offset by a valuation allowance. Utilization of net operating loss and credit carryforwards may be subject to substantial annual limitation due to ownership change provisions of Section 382 of the Internal Revenue Code, as amended and similar state provisions. The annual limitation may result in the expiration of net operating losses and credits before utilization. As of both March 31, 2022 and December 31, 2021, the Company’s liability for gross unrecognized tax benefits (excluding interest and penalties) totaled $ 0 0 0 0

Long-Term Debt

Long-Term Debt	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Long-Term Debt	Note 8. Long-Term Debt Long-term debt as of March 31, 2022 and December 31, 2021 consists of a $ 57 1 2020 Convertible Notes Effective February 8, 2021 the Company’s shareholders and 2020 Convertible Note holders approved amendments to the 2020 Convertible Notes to allow for the issuance of up to $ 10.0 3.9 3.0 10.0 5.0 3.9 5 For any Major Investor, the modified terms provide for a fixed conversion discount on the 2020 Convertible Notes of 20% and a common stock warrant equal to 20% of the amount invested in all 2020 Convertible Notes by such Major Investor divided by the weighted average share price of the Common Stock over the five trading days prior to the closing of the Merger 1.25 3.0 143,890 5.9059 12.7 468 3,338,944 2.5 18.22 Payroll Protection Plan Loan In April 2020, the Company applied for and received a $ 730 thousand loan under the Payroll Protection Plan (“PPP”) as part of the Coronavirus Aid, Relief, and Economic Security Act’s (“CARES Act”). Under the PPP, the Company was able to receive funds for two and a half months of payroll, rent, utilities, and interest cost. In April 2021 the SBA fully forgave the PPP loan. The $ 730 thousand of PPP loan forgiveness was recorded as a reduction of operating costs during 2020. Economic Injury Disaster Loan The Company applied for and received a $ 57 10 3.75 repayable in monthly installments starting in June 2022

Stockholders_ Equity

Stockholders’ Equity	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Stockholders’ Equity	Note 9. Stockholders’ Equity Common Stock Holders of common stock are entitled to one vote per share, to receive dividends if and when declared, and, upon liquidation or dissolution, are entitled to receive all assets available for distribution to stockholders. The holders have no preemptive or other subscription rights and there are no redemption or sinking fund provisions with respect to such shares. Common stock is subordinate to the preferred stock with respect to dividend rights and rights upon liquidation, winding up and dissolution of the Company. Lincoln Park Capital Fund, LLC Agreement On March 28, 2022, the Company entered into a purchase agreement, or Purchase Agreement, with Lincoln Park Capital Fund, LLC (“Lincoln Park”), which, subject to the terms and conditions, provides that the Company has the right to sell to Lincoln Park and Lincoln Park is obligated to purchase up to $ 15.0 million of its common shares. Additionally, on March 28, 2022, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) with Lincoln Park, pursuant to which the Company agreed to file a registration statement with the Securities and Exchange Commission (the “SEC”), covering the resale of shares of common stock issued to Lincoln Park under the Purchase Agreement. In addition, under the Purchase Agreement, the Company agreed to issue a commitment fee of 405,953 common shares, or the Commitment Shares, as consideration for Lincoln Park entering into the Purchase Agreement. Under the Purchase Agreement, the Company may from time to time for 30 months following May 9, 2022 (the “Commencement Date”), at its discretion, direct Lincoln Park to purchase on any single business day, or a Regular Purchase, up to (i) 50,000 common shares, (ii) 75,000 common shares if the closing sale price of its common shares is not below $1.50 per share on Nasdaq or (iii) 100,000 common shares if the closing sale price of its common shares is not below $2.50 per share on Nasdaq. In addition to Regular Purchases, the Company may also direct Lincoln Park to purchase other amounts as accelerated purchases or as additional accelerated purchases on the terms and subject to the conditions set forth in the Purchase Agreement. In any case, Lincoln Park’s commitment in any single Regular Purchase may not exceed $1.0 million absent a mutual agreement to increase such amount. The purchase price per share for each Regular Purchase will be based on prevailing market prices of the Common Stock immediately preceding the time of sale as computed in accordance with the terms set forth in the Purchase Agreement. There are no upper limits on the price per share that Lincoln Park must pay for shares of Common Stock under the Purchase Agreement. The Purchase Agreement may be terminated by the Company at any time after the Commencement Date, at its sole discretion, without any cost or penalty, by giving one business day notice to Lincoln Park to terminate the Purchase Agreement. For the quarter ended March 31, 2022, the Company incurred $ 101 thousand of issuance costs related to Lincoln Park and Canaccord Genuity LLC At The Market (“ATM”) (see Note 16. Subsequent Events) Preferred Stock Series A and B Preferred Stock As of December 31, 2020, the Company had 4,611,587 shares of Series A Preferred Stock (the “Series A Preferred”) 3,489,470 shares of Series B Preferred Stock (the “Series B”) issued and outstanding (collectively the “Preferred Stock”). The Company had classified the Preferred Stock as temporary equity in the condensed consolidated balance sheets as the Preferred Shareholders controlled a Deemed Liquidation Event, as defined below, under the terms of the Series A and Series B Preferred Stock as described below. Effective with the Merger, all the Series A Preferred and the Series B Preferred shares were exchanged for 5,973,509 and 4,524,171 shares of common stock, respectively, and t he related carrying value was reclassified to common stock and additional paid-in capital. Series C Preferred Stock Effective March 15, 2021, StemoniX’s shareholders approved the Merger with Cancer Genetics and the authorization of $ 2.0 million of StemoniX’s Series C Preferred Stock (“Series C Preferred”). Effective with the Merger on March 30, 2021, the Series C Preferred shares were exchanged for 699,395 shares of Vyant Bio common stock and t he related carrying value was reclassified to common stock and additional paid-in capital. Warrants Common Stock Warrants The Company issued the Investor Warrant on February 23, 2021. Effective with the Merger, the Investor Warrant was exchanged for a warrant to purchase 143,890 shares of the Company’s common stock at an exercise price of $ 5.9059 . Prior to this exchange, the Investor Warrant was classified as a liability and the Company recognized a $ 214 thousand gain in the first quarter of 2021 related to fair value adjustments. The fair value of the Investor Warrant was $ 421 thousand at the time of the Merger and reclassified to additional paid in capital. In connection with the Merger, the Company assume d 2,157,686 2,149,106 Summary of All Common Stock Warrants Outstanding Issuance Related to: Exercise Price Outstanding Warrants Expiration Dates 2020 Convertible Note $ 5.91 143,890 Feb 23, 2026 2021 offerings $ 3.50 1,624,140 Feb 10, 2026 - Aug 3, 2026 Advisory fees $ 2.42 7.59 492,894 Jan 9, 2024 - Oct 28, 2025 Debt $ 27.60 14,775 Mar 22, 2024 Debt $ 450.00 9,185 Oct 17, 2022 - Dec 7, 2022 Debt $ 300.00 8,112 Oct 17, 2022 Total 2,292,996 Preferred Stock Warrants In connection with the issuance of the Series A Convertible Preferred and Series B Convertible Preferred, the Company issued warrants (the “Series A Warrants” and “Series B Warrants”, respectively, and collectively, the “Preferred Warrants”) as compensation to non-employee placement agents. The Series A Warrants and Series B Warrants were issued on April 28, 2017 and May 18, 2019, respectively. The Company determined the Preferred Warrants should be classified as equity as they were issued as vested share-based payment compensation to nonemployees. The Preferred Warrants were recorded in stockholders’ equity at fair value upon issuance with no subsequent remeasurement. As part of the Merger, the Preferred Warrants were converted and settled for a total of 43,107

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 10. Fair Value Measurements During the first quarter of 2021, the Company elected to account for the $ 3.0 The fair value of the Company’s 2020 Convertible Note issued to the Major Investor is measured as the sum of the instrument’s parts, being the underlying debt instrument and the conversion feature. The conversion feature was valued using the probability weighted conversion price discount. The instrument provided the holder the right to convert the instrument into shares of Series B Preferred Stock at a 20% discount. Given the timing of the issuance of the instrument near the Merger date, management determined that there was a 99.5% probability of the holders converting the instrument to Company shares at a 20% discount . The Company valued the warrants issued with the 2020 Convertible Notes using a Black-Scholes-Merton model using the value of the underlying stock and exercise price of $ 2.01 0.59 86 5 The Company’s 2020 Convertible Notes contain a share settled redemption feature (“Embedded Derivative”) that requires conversion at the lesser of specified discounts from qualified financing price per share or the fair value of the common stock at the time of conversion. The discount changes based on the passage of time between issuance of the convertible note and the conversion event. This feature is considered a derivative that requires bifurcation because it provides a specified premium to the holder of the note upon conversion. The Company measures the share-settlement obligation derivative at fair value based on significant inputs that are not observable in the market. This results in the liability classified as a Level 3 measurement within the fair value hierarchy. Upon the Merger, all of the Level 3 instruments were exchanged for Vyant Bio equity classified instruments. Prior to their exchange, all of these instruments were marked to their fair market values with corresponding changes recorded in the statement of operations in the first quarter of 2021. In the fourth quarter of 2021, the Company classified the vivo vivo vivo 4.5 vivo vivo 11.0 million and $ 6.5 million as of December 31, 2021 and March 31, 2022, respectively. The Company recognized an impairment charge of $ 4.3 vivo 9.2 million as of December 31, 2021 to $ 4.9 million as of March 31, 2022. The following tables present changes in fair value of level 3 valued instruments as of and for the three months ended March 31, 2022 and 2021: Schedule of Changes in Fair Value of Level 3 Valued Instruments vivo Balance – January 1, 2022 $ 11,000 Additions - Measurement adjustments (4,500 ) Settlement - Balance – March 31, 2022 $ 6,500 2020 Convertible Note Warrant Embedded Derivative Balance – January 1, 2021 $ - $ - $ 1,690 Additions 3,746 635 325 Measurement adjustments 4 (214 ) 250 Settlement (3,750 ) (421 ) (2,265 ) Balance – March 31, 2021 $ - $ - $ -

Loss Per Share

Loss Per Share	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Loss Per Share	Note 11. Loss Per Share Basic loss per share is computed by dividing the net loss after tax attributable to common stockholders by the weighted average shares outstanding during the period. Diluted loss per share is computed by including potentially dilutive securities outstanding during the period in the calculation of weighted average shares outstanding. The Company did not have any dilutive securities during the periods presented; therefore, diluted loss per share is equal to basic loss per share.   Presented in the table below is a reconciliation of the numerator and denominator for the basic and diluted loss per share calculations for the three months ended March 31, 2022 and 2021: Schedule of Reconciliation of Numerator and Denominator for Basic and Diluted Loss Per Share 2022 2021 March 31, 2022 2021 Net loss from continuing operations $ (4,406 ) $ (7,358 ) Net loss from discontinuing operations (4,757 ) (8 ) Net loss $ (9,163 ) $ (7,366 ) Basic and diluted weighted average shares outstanding 29,012,536 3,184,106 Basic and diluted net loss per share: Continuing operations $ (0.15 ) $ (2.31 ) Discontinuing operations (0.17 ) - Net loss $ (0.32 ) $ (2.31 ) The following securities were not included in the computation of diluted shares outstanding for the for the three months ended March 31, 2022 and 2021 because the effect would be anti-dilutive: Schedule of Computation of Diluted Shares Outstanding 2022 2021 March 31, 2022 2021 Common stock warrants 2,292,996 2,301,576 Common stock options 2,766,616 2,268,543 Total 5,059,612 4,570,119

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2022
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	Note 12. Stock-Based Compensation The Company has two pre-Merger legacy equity incentive plans: the Cancer Genetics Inc. 2011 Equity Incentive Plan (the “2011 Plan”), and the StemoniX Inc. 2015 Stock Option Plan (the “2015 Plan”, and collectively, the “ Frozen Stock Option Plans”). The Frozen Stock Option Plans as well as the 2021 Plan (as defined below) are meant to provide additional incentive to officers, employees and consultants to remain in the Company’s employment. Options granted are generally exercisable for up to 10 the Company is no longer able to issue options from the Frozen Stock Option Plans. 4,500,000 As StemoniX was the acquirer for accounting purposes, the pre-Merger vested stock options granted by CGI under the 2008 and 2011 Plans are deemed to have been exchanged for equity awards of the Company. The exchange of StemoniX stock options for options to purchase Company common stock was accounted for as a modification of the StemoniX stock options; however, the modification did not result in any incremental compensation expense as the modification did not increase the fair value of the stock options. For StemoniX stock options issued prior to the Merger, the expected volatility was estimated based on the average historical volatility of similar entities with publicly traded shares as StemoniX’s shares historically were not publicly traded and its shares rarely traded privately. After the Merger, the Company used Vyant’s historical volatility to determine the expected volatility of post-Merger option grants. The risk-free rate for the expected term of the option is based on the U.S. Treasury yield curve at the date of grant. The Company uses a simplified method to determine the expected term for the valuation of employee options. This method effectively assumes that exercise occurs over the period from vesting until expiration, and therefore the expected term is the midpoint between the service period and the contractual term of the award. The simplified method is applicable to options with service conditions. For options granted to nonemployees, the contractual term is used for the valuation of the options. On March 30, 2021, the Company granted 1,151,500 78,090 8,676 25% During the three-month period ended March 31, 2022, the Company granted 725,301 stock options to officers and other employees, 350,896 restricted stock units (“RSUs”) to the Company’s Board of Directors. The options granted to officers and employees vest over various terms based on the underlying agreement as 606,720 contain performance vesting criteria. The RSUs granted to Board members vests one year from the grant date. As of March 31, 2022, there were 2,228,537 Schedule of Assumptions for Stock Option Grants 2022 2021 Valuation assumptions Expected dividend yield 0.0 % 0.0 % Expected volatility 56.3 69.8 % 119 123 % Expected term (years) – simplified method 3.0 6.1 5.5 6.0 Risk-free interest rate 1.74 2.13 % 0.98 1.12 % Stock option activity during the for the three-month periods ended March 31, 2022 and 2021 is as follows: Schedule of Share Option Activity Number of Options Weighted average exercise price Weighted average remaining contractual term Balance as of January 1, 2021 756,383 $ 1.82 8.7 Granted 1,229,590 4.61 Additional options grant StemoniX holders 292,995 4.61 Options assumed in Merger 55,840 45.95 Exercised (29,916 ) 1.24 Forfeited (29,349 ) 2.00 Expired (7,000 ) 1.39 Balance as of March 31, 2021 2,268,543 $ 4.79 8.1 Balance as of January 1, 2022 2,320,097 4.19 7.4 Granted 725,301 1.01 Exercised (5,174 ) 0.96 Forfeited (255,766 ) 4.22 Expired (17,842 ) 57.24 Balance as of March 31, 2022 2,766,616 $ 3.01 8.7 Exercisable as of March 31, 2022 1,011,626 $ 3.72 7.6 The weighted average grant-date fair value of options granted during the three-month periods ended March 31, 2022 and 2021 was $ 0.54 3.89 0.1 0.1 1 23 The Company recognized stock-based compensation in continuing operations related to different instruments for the three-month periods ended March 31 as follows: Schedule of Share Based Compensation Activity 2022 2021 Stock options $ 258 $ 366 Shares issued for services 20 - Total $ 278 $ 366 As of March 31, 2022, there was $ 3.5 2.75

Segment Information

Segment Information	3 Months Ended
	Mar. 31, 2022
Segment Reporting [Abstract]
Segment Information	Note 13. Segment Information The Company reports segment information based on how the Company’s chief operating decision maker (“CODM”), regularly reviews operating results, allocates resources and makes decisions regarding business operations. For segment reporting purposes, the Company’s business structure is comprised of one operating and reportable segment. During the three-months ended March 31, 2022 and 2021, four customers and three customers accounted for approximately 76 % and 69 During the three-months ended March 31, 2022 and 2021, approximately 33 % and 38 %, respectively, of the Company’s consolidated revenue from continuing operations were earned outside of the U.S. Customers representing 10% or more of the Company’s total revenue from continuing operations for the three-month periods ended March 31, 2022 and 2021 are presented in the table below: Schedule of Customers Representing Revenues 2022 2021 Customer A 27 % 24 % Customer B 24 % 28 % Customer C 14 % n/a Customer D 11 % n/a Customer E n/a 17 %

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2022
Related Party Transactions [Abstract]
Related Party Transactions	Note 14. Related Party Transactions The Company raised approximately $ 3.9 143,890 5.9059 During the first quarter of 2022, the Company paid a third-party collaboration partner $ 39

Contingencies

Contingencies	3 Months Ended
	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Note 15. Contingencies We are not currently subject to any material legal proceedings. However, we may from time to time become a party to various legal proceedings arising in the ordinary course of our business.

Subsequent Event

Subsequent Event	3 Months Ended
	Mar. 31, 2022
Subsequent Events [Abstract]
Subsequent Event	Note 16. Subsequent Event At The Market Financing On April 8, 2022, the Company entered into an Equity Distribution Agreement (the “Sales Agreement”) with Canaccord Genuity LLC (the “Agent”), pursuant to which the Company may issue and sell, from time to time, shares of its common stock having an aggregate offering price of up to $ 20,000,000 3.0 75,000

Cancer Genetics, Inc. Merger (T

Cancer Genetics, Inc. Merger (Tables)	3 Months Ended
	Mar. 31, 2022
Business Combination and Asset Acquisition [Abstract]
Schedule of Preliminary Allocation of the Purchase Price Consideration	Schedule of Preliminary Allocation of the Purchase Price Consideration Preliminary Adjustments Final Assets acquired: Cash and equivalents $ 30,163 $ - $ 30,163 Accounts receivable 705 - 705 Other current assets 806 227 1,033 Intangible assets 9,500 - 9,500 Fixed assets 416 (256 ) 160 Goodwill 22,164 216 22,380 Long-term prepaid expenses and other assets 1,381 - 1,381 Total assets acquired $ 65,135 $ 187 $ 65,322 Liabilities assumed: Accounts payable and accrued expenses $ 2,670 $ 437 $ 3,107 Current liabilities of discontinuing operations 588 (141 ) 447 Obligations under operating leases 198 - 198 Obligations under finance leases 106 - 106 Deferred revenue 1,293 (114 ) 1,179 Payroll and income taxes payable 360 5 365 Total liabilities assumed $ 5,215 $ 187 $ 5,402 Net assets acquired: $ 59,920 $ - $ 59,920
Schedule of Proforma Financial Information	The following presents the unaudited pro forma combined financial information as if the Merger had occurred as of January 1, 2020: Schedule of Proforma Financial Information March 31, 2021 Total revenue $ 1,841 Net loss $ (6,495 ) Pro forma loss per common share, basic and diluted $ (.21 ) Pro forma weighted average number of common shares outstanding, basic and diluted 28,985

Discontinuing Operations (Table

Discontinuing Operations (Tables)	3 Months Ended
	Mar. 31, 2022
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Discontinuing Operations from Income Statement and Balance Sheet	Results of discontinuing operations were as follows for the three months ended March 31, 2022: Schedule of Discontinuing Operations from Income Statement and Balance Sheet Revenue $ 1,353 Cost of goods sold 775 General and administrative 1,045 Impairment of goodwill and intangible assets 4,290 Total operating costs and expenses 6,110 Loss from discontinuing operations (4,757 ) Total other income - Loss from discontinuing operations before income taxes (4,757 ) Income tax benefit - Net loss from discontinuing operations $ (4,757 ) Asset and liabilities of discontinuing operations were as follows as of March 31, 2022 and December 31, 2021: March 31, December 31, 2021 Accounts receivable $ 542 $ 457 Other current assets 459 345 Assets of discontinuing operations - current 1,001 802 Fixed assets, net of accumulated depreciation 191 163 Operating lease right-of-use assets 941 30 Intangible assets, net 6,634 8,787 Goodwill - 2,164 Other assets 362 364 Assets of discontinuing operations - non-current 8,128 11,508 Accounts payable $ 442 $ 358 Accrued expense 417 418 Obligation under operating lease, current 151 29 Obligation under finance lease, current 34 32 Deferred revenue 1,942 1,911 Taxes payable 365 365 Other current liabilities 409 409 Liabilities of discontinued operations - current 3,760 3,522 Obligations under operating leases, less current 794 2 Obligations under finance leases, less current 40 47 Liabilities of discontinued operations - non-current 834 49
Schedule of Intangible Assets	Intangible assets consisted of the following as of March 31, 2022 and December 31, 2021: Schedule of Intangible Assets March 31, 2022 December 31, 2021 Customer relationships $ 6,187 $ 8,000 Trade name 1,160 1,500 Intangible assets, net 7,347 9,500 Less accumulated amortization (713 ) (713 ) Intangible assets, net $ 6,634 $ 8,787
Schedule of Goodwill Rollforward	Goodwill arising from the Merger was solely attributed to the vivo Schedule of Goodwill Rollforward 2022 Beginning balance, January 1 $ 2,164 Purchase price adjustments - Impairment charge (2,164 ) Ending balance, March 31 $ -

Inventory (Tables)

Inventory (Tables)	3 Months Ended
	Mar. 31, 2022
Inventory Disclosure [Abstract]
Schedule of Inventory	The Company’s inventory consists of the following: Schedule of Inventory March 31, December 31, 2021 Finished goods $ 56 $ 23 Work in process 51 138 Raw materials 390 314 Total inventory $ 497 $ 475

Fixed Assets (Tables)

Fixed Assets (Tables)	3 Months Ended
	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Schedule of Fixed Assets	Presented in the table below are the major classes of fixed assets by category: Schedule of Fixed Assets March 31, December 31, 2021 Equipment $ 2,752 $ 2,733 Furniture and fixtures 6 6 Leasehold improvements 261 251 Fixed assets, gross 3,019 2,990 Less accumulated depreciation (2,111 ) (1,970 Total $ 908 $ 1,020

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2022
Leases
Components of Lease Expense and Supplemental Information	The components of operating and finance lease expenses for the three-month periods ended March 31, are as follows: Components of Lease Expense and Supplemental Information 2022 2021 Operating lease costs $ 98 $ 107 Finance lease costs: Depreciation of ROU assets 40 - Interest on lease liabilities 7 - Total finance lease cost 47 - Variable lease costs - - Short-term lease costs - - Total lease cost $ 145 $ 107 Other information related to leases from continuing operations for the three-month periods ended March 31, are as follows: 2022 2021 Supplemental cash flow information: Cash paid for amounts included in the measurement of lease liabilities: Operating cash flow from operating leases $ 98 $ 117 Financing cash flow from finance leases 34 - Weighted average remaining lease term: Operating leases 5.18 5.65 Finance leases 2.5 - Weighted average discount rate: Operating leases 8.3 % 9.6 % Finance leases 6.5 % 8.1 %
Schedule of Amounts Reported in the Consolidated Balance Sheet	Amounts reported in the condensed consolidated balance sheets as of March 31, 2022 and December 31, 2021 are as follows: Schedule of Amounts Reported in the Consolidated Balance Sheet 2022 2021 Operating leases: Operating lease ROU assets, net $ 1,764 $ 673 Operating lease current liabilities 241 174 Operating lease long-term liabilities 1,540 516 Total operating lease liabilities 1,781 690 Finance leases: Equipment 477 477 Accumulated depreciation (79 ) (63 ) Finance leases, net 398 414 Current installment obligations under finance leases 158 157 Long-term portion of obligations under finance leases 258 293 Total finance lease liabilities $ 416 $ 450
Schedule of Annual Payments of Lease Liabilities Under Noncancelable Leases	Annual payments of lease liabilities under noncancelable leases from continuing operations as of March 31, 2022 are as follows: Schedule of Annual Payments of Lease Liabilities Under Noncancelable Leases Operating leases Finance leases Remainder of 2022 $ 303 $ 136 2023 433 181 2024 423 136 2025 427 - 2026 441 - 2027 200 - Thereafter - - Total undiscounted lease payments 2,227 452 Less: Imputed interest (446 ) (36 ) Total lease liabilities $ 1,781 $ 416

Stockholders_ Equity (Tables)

Stockholders’ Equity (Tables)	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Summary of All Common Stock Warrants Outstanding	Summary of All Common Stock Warrants Outstanding Issuance Related to: Exercise Price Outstanding Warrants Expiration Dates 2020 Convertible Note $ 5.91 143,890 Feb 23, 2026 2021 offerings $ 3.50 1,624,140 Feb 10, 2026 - Aug 3, 2026 Advisory fees $ 2.42 7.59 492,894 Jan 9, 2024 - Oct 28, 2025 Debt $ 27.60 14,775 Mar 22, 2024 Debt $ 450.00 9,185 Oct 17, 2022 - Dec 7, 2022 Debt $ 300.00 8,112 Oct 17, 2022 Total 2,292,996

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Schedule of Changes in Fair Value of Level 3 Valued Instruments	The following tables present changes in fair value of level 3 valued instruments as of and for the three months ended March 31, 2022 and 2021: Schedule of Changes in Fair Value of Level 3 Valued Instruments vivo Balance – January 1, 2022 $ 11,000 Additions - Measurement adjustments (4,500 ) Settlement - Balance – March 31, 2022 $ 6,500 2020 Convertible Note Warrant Embedded Derivative Balance – January 1, 2021 $ - $ - $ 1,690 Additions 3,746 635 325 Measurement adjustments 4 (214 ) 250 Settlement (3,750 ) (421 ) (2,265 ) Balance – March 31, 2021 $ - $ - $ -

Loss Per Share (Tables)

Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Schedule of Reconciliation of Numerator and Denominator for Basic and Diluted Loss Per Share	Presented in the table below is a reconciliation of the numerator and denominator for the basic and diluted loss per share calculations for the three months ended March 31, 2022 and 2021: Schedule of Reconciliation of Numerator and Denominator for Basic and Diluted Loss Per Share 2022 2021 March 31, 2022 2021 Net loss from continuing operations $ (4,406 ) $ (7,358 ) Net loss from discontinuing operations (4,757 ) (8 ) Net loss $ (9,163 ) $ (7,366 ) Basic and diluted weighted average shares outstanding 29,012,536 3,184,106 Basic and diluted net loss per share: Continuing operations $ (0.15 ) $ (2.31 ) Discontinuing operations (0.17 ) - Net loss $ (0.32 ) $ (2.31 )
Schedule of Computation of Diluted Shares Outstanding	The following securities were not included in the computation of diluted shares outstanding for the for the three months ended March 31, 2022 and 2021 because the effect would be anti-dilutive: Schedule of Computation of Diluted Shares Outstanding 2022 2021 March 31, 2022 2021 Common stock warrants 2,292,996 2,301,576 Common stock options 2,766,616 2,268,543 Total 5,059,612 4,570,119

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2022
Share-Based Payment Arrangement [Abstract]
Schedule of Assumptions for Stock Option Grants	Schedule of Assumptions for Stock Option Grants 2022 2021 Valuation assumptions Expected dividend yield 0.0 % 0.0 % Expected volatility 56.3 69.8 % 119 123 % Expected term (years) – simplified method 3.0 6.1 5.5 6.0 Risk-free interest rate 1.74 2.13 % 0.98 1.12 %
Schedule of Share Option Activity	Stock option activity during the for the three-month periods ended March 31, 2022 and 2021 is as follows: Schedule of Share Option Activity Number of Options Weighted average exercise price Weighted average remaining contractual term Balance as of January 1, 2021 756,383 $ 1.82 8.7 Granted 1,229,590 4.61 Additional options grant StemoniX holders 292,995 4.61 Options assumed in Merger 55,840 45.95 Exercised (29,916 ) 1.24 Forfeited (29,349 ) 2.00 Expired (7,000 ) 1.39 Balance as of March 31, 2021 2,268,543 $ 4.79 8.1 Balance as of January 1, 2022 2,320,097 4.19 7.4 Granted 725,301 1.01 Exercised (5,174 ) 0.96 Forfeited (255,766 ) 4.22 Expired (17,842 ) 57.24 Balance as of March 31, 2022 2,766,616 $ 3.01 8.7 Exercisable as of March 31, 2022 1,011,626 $ 3.72 7.6
Schedule of Share Based Compensation Activity	The Company recognized stock-based compensation in continuing operations related to different instruments for the three-month periods ended March 31 as follows: Schedule of Share Based Compensation Activity 2022 2021 Stock options $ 258 $ 366 Shares issued for services 20 - Total $ 278 $ 366

Segment Information (Tables)

Segment Information (Tables)	3 Months Ended
	Mar. 31, 2022
Segment Reporting [Abstract]
Schedule of Customers Representing Revenues	Customers representing 10% or more of the Company’s total revenue from continuing operations for the three-month periods ended March 31, 2022 and 2021 are presented in the table below: Schedule of Customers Representing Revenues 2022 2021 Customer A 27 % 24 % Customer B 24 % 28 % Customer C 14 % n/a Customer D 11 % n/a Customer E n/a 17 %

Schedule of Preliminary Allocat

Schedule of Preliminary Allocation of the Purchase Price Consideration (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Mar. 30, 2022	Dec. 31, 2021
Business Acquisition [Line Items]
Goodwill			$ 2,164
StemoniX [Member]
Business Acquisition [Line Items]
Cash and equivalents		$ 30,163
Accounts receivable		705
Other current assets		1,033
Intangible assets		9,500
Fixed assets		160
Goodwill		22,380
Long-term prepaid expenses and other assets		1,381
Total assets acquired		65,322
Accounts payable and accrued expenses		3,107
Current liabilities of discontinuing operations		447
Obligations under operating leases		198
Obligations under finance leases		106
Deferred revenue		1,179
Payroll and income taxes payable		365
Total liabilities assumed		5,402
Net assets acquired:		59,920
StemoniX [Member] | Previously Reported [Member]
Business Acquisition [Line Items]
Cash and equivalents		30,163
Accounts receivable		705
Other current assets		806
Intangible assets		9,500
Fixed assets		416
Goodwill		22,164
Long-term prepaid expenses and other assets		1,381
Total assets acquired		65,135
Accounts payable and accrued expenses		2,670
Current liabilities of discontinuing operations		588
Obligations under operating leases		198
Obligations under finance leases		106
Deferred revenue		1,293
Payroll and income taxes payable		360
Total liabilities assumed		5,215
Net assets acquired:		59,920
StemoniX [Member] | Revision of Prior Period, Adjustment [Member]
Business Acquisition [Line Items]
Cash and equivalents
Accounts receivable
Other current assets		227
Intangible assets
Fixed assets		(256)
Goodwill		216
Long-term prepaid expenses and other assets
Total assets acquired		187
Accounts payable and accrued expenses		437
Current liabilities of discontinuing operations		(141)
Obligations under operating leases
Obligations under finance leases
Deferred revenue		(114)
Payroll and income taxes payable		5
Total liabilities assumed		187
Net assets acquired:

Schedule of Proforma Financial

Schedule of Proforma Financial Information (Details) $ / shares in Units, $ in Thousands	1 Months Ended
	Mar. 31, 2022USD ($)$ / sharesshares
Business Combination and Asset Acquisition [Abstract]
Total revenue	$ 1,841
Net loss	$ (6,495)
Pro forma loss per common share, basic and diluted | $ / shares	$ (0.21)
Pro forma weighted average number of common shares outstanding, basic and diluted | shares	28,985

Cancer Genetics, Inc. Merger (D

Cancer Genetics, Inc. Merger (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	Mar. 30, 2021	Aug. 21, 2020	Mar. 31, 2022	Mar. 31, 2021	Mar. 30, 2022	Dec. 31, 2021	Feb. 23, 2021
Business Acquisition [Line Items]
Common stock, par or stated value per share			$ 0.0001			$ 0.0001
Business combination, acquisition related costs				$ 2,145
Revenue percentage, description			Key assumptions in this analysis included an estimated 10% annual customer attrition rate based on historical vivoPharm operations, a blended U.S. federal, state and Australian income tax rate of 27.1%, a present value factor of 8.5% as well as revenue, cost of revenue and operating expense assumptions regarding the future growth, operating expenses, including corporate overhead charges, and required capital investments
Common Stock [Member]
Business Acquisition [Line Items]
Stock issued during period, shares, new issues			406,000	805,000
StemoniX [Member]
Business Acquisition [Line Items]
Assets acquired and liabilities assumed, current liabilities, accounts payable					$ 3,107
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles					$ 9,500
StemoniX [Member] | Merger Agreement [Member]
Business Acquisition [Line Items]
Stock issued during period, shares, new issues	804,711
Business combination consideration transferred	$ 59,900
StemoniX [Member] | Merger Agreement [Member] | Common Stock [Member]
Business Acquisition [Line Items]
Stock issued during period, shares, new issues	11,007,186
Business combination, step acquisition, equity interest in acquiree, fair value	$ 50,740
StemoniX [Member] | Merger Agreement [Member] | Common Stock Warrants [Member]
Business Acquisition [Line Items]
Stock issued during period, shares, new issues	2,157,686
Business combination, step acquisition, equity interest in acquiree, fair value	$ 9,040
StemoniX [Member] | Merger Agreement [Member] | Common Stock Options [Member]
Business Acquisition [Line Items]
Stock issued during period, shares, new issues	55,907
Business combination, step acquisition, equity interest in acquiree, fair value	$ 139
StemoniX [Member] | Holders [Member] | Merger Agreement [Member]
Business Acquisition [Line Items]
Stock issued during period, shares, new issues		17,977,544
Common stock, par or stated value per share		$ 0.0001
Share-based payment award, shares purchased for award		891,780
Share-based payment arrangement, option, exercise price range, lower range limit		$ 0.66
Share-based payment arrangement, option, exercise price range, upper range limit		4.61
Exercise price range, exercisable, weighted average exercise price		$ 1.46
StemoniX [Member] | Investor [Member] | Merger Agreement [Member]
Business Acquisition [Line Items]
Share-based payment award, shares purchased for award		143,890
Shares issued, price per share		$ 5.9059	$ 5.9059				$ 5.9059
StemoniX and Cancer Genetics Inc [Member] | Merger Agreement [Member]
Business Acquisition [Line Items]
Business combination, acquisition related costs				$ 2,145
Assets acquired and liabilities assumed, current liabilities, accounts payable				$ 63
StemoniX and Cancer Genetics Inc [Member] | Merger Agreement [Member] | Trade Names [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			$ 1,500
StemoniX and Cancer Genetics Inc [Member] | Merger Agreement [Member] | Customer Relationships [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			$ 8,000
Royalty payment, percentage			1.00%

Schedule of Discontinuing Opera

Schedule of Discontinuing Operations from Income Statement and Balance Sheet (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Assets of discontinuing operations - current	$ 1,001	$ 802
Assets of discontinuing operations - non-current	8,128	11,508
Liabilities of discontinued operations - current	3,760	3,522
Liabilities of discontinued operations - non-current	834	49
Vivo Pharm Disposal [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenue	1,353
Cost of goods sold	775
General and administrative	1,045
Impairment of goodwill and intangible assets	4,290
Total operating costs and expenses	6,110
Loss from discontinuing operations	(4,757)
Total other income
Loss from discontinuing operations before income taxes	(4,757)
Income tax benefit
Net loss from discontinuing operations	(4,757)
Accounts receivable	542	457
Other current assets	459	345
Assets of discontinuing operations - current	1,001	802
Fixed assets, net of accumulated depreciation	191	163
Operating lease right-of-use assets	941	30
Intangible assets, net	6,634	8,787
Goodwill		2,164
Other assets	362	364
Assets of discontinuing operations - non-current	8,128	11,508
Accounts payable	442	358
Accrued expense	417	418
Obligation under operating lease, current	151	29
Obligation under finance lease, current	34	32
Deferred revenue	1,942	1,911
Taxes payable	365	365
Other current liabilities	409	409
Liabilities of discontinued operations - current	3,760	3,522
Obligations under operating leases, less current	794	2
Obligations under finance leases, less current	40	47
Liabilities of discontinued operations - non-current	$ 834	$ 49

Schedule of Intangible Assets (

Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Intangible assets, net	$ 7,347	$ 9,500
Less accumulated amortization	(713)	(713)
Intangible assets, net	6,634	8,787
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, net	6,187	8,000
Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, net	$ 1,160	$ 1,500

Schedule of Goodwill Rollforwar

Schedule of Goodwill Rollforward (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)
Discontinued Operations and Disposal Groups [Abstract]
Beginning balance	$ 2,164
Purchase price adjustments
Impairment charge	(2,164)
Ending balance

Discontinuing Operations (Detai

Discontinuing Operations (Details Narrative) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Asset Impairment Charges	$ 4,300	$ 20,200
Goodwill, Written off Related to Sale of Business Unit	2,200
Disposal group, including discontinued operation, liabilities, current	3,760	3,522
Increase decrease of right-of-use asset	1,000
Cancer Genetics Inc [Member]
Finite-Lived Intangible Assets [Line Items]
Disposal group, including discontinued operation, liabilities, current	409	$ 409
Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)	300
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)	$ 1,800

Schedule of Inventory (Details)

Schedule of Inventory (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Finished goods	$ 56	$ 23
Work in process	51	138
Raw materials	390	314
Total inventory	$ 497	$ 475

Schedule of Fixed Assets (Detai

Schedule of Fixed Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Fixed assets, gross	$ 3,019	$ 2,990
Less accumulated depreciation	(2,111)	(1,970)
Total	908	1,020
Equipment [Member]
Property, Plant and Equipment [Line Items]
Fixed assets, gross	2,752	2,733
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Fixed assets, gross	6	6
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Fixed assets, gross	$ 261	$ 251

Fixed Assets (Details Narrative

Fixed Assets (Details Narrative) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Depreciation	$ 142	$ 126

Components of Lease Expense and

Components of Lease Expense and Supplemental Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Leases
Operating lease costs	$ 98,000	$ 107,000
Depreciation of ROU assets	40,000
Interest on lease liabilities	7,000
Total finance lease cost	47,000
Variable lease costs
Short-term lease costs
Total lease cost	145,000	107,000
Cash paid for amounts included in the measurement of lease liabilities:
Operating lease payments	98	117
Finance lease and interest payments	$ 34
Weighted average remaining lease term:
Operating lease, weighted average remaining lease term	5 years 2 months 4 days	5 years 7 months 24 days
Finance leaseweighted average remaining lease term	2 years 6 months
Weighted average discount rate:
Operating lease, weighted average discount rate, percent	8.30%	9.60%
Finance leaseweighted average discount rate, percent	6.50%	8.10%

Schedule of Amounts Reported in

Schedule of Amounts Reported in the Consolidated Balance Sheet (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Leases
Operating lease ROU assets, net	$ 1,764	$ 673
Operating lease current liabilities	241	174
Operating lease long-term liabilities	1,540	516
Total operating lease liabilities	1,781	690
Equipment	477	477
Accumulated depreciation	(79)	(63)
Finance leases, net	398	414
Current installment obligations under finance leases	158	157
Long-term portion of obligations under finance leases	258	293
Total finance lease liabilities	$ 416	$ 450

Schedule of Annual Payments of

Schedule of Annual Payments of Lease Liabilities Under Noncancelable Leases (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Lessee, Lease, Description [Line Items]
Total lease liabilities	$ 1,781	$ 690
Operating Leases [Member]
Lessee, Lease, Description [Line Items]
Remainder of 2022	303
2023	433
2024	423
2025	427
2026	441
2027	200
Thereafter
Total undiscounted lease payments	2,227
Less: Imputed interest	(446)
Total lease liabilities	1,781
Finance Leases [Member]
Lessee, Lease, Description [Line Items]
Remainder of 2022	136
2023	181
2024	136
2025
2026
2027
Thereafter
Total undiscounted lease payments	452
Less: Imputed interest	(36)
Total lease liabilities	$ 416

Leases (Details Narrative)

Leases (Details Narrative) $ in Millions	Jan. 30, 2022USD ($)
Lease Liabilities [Member]
Finance lease, right-of-use asset	$ 1.2

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Unrecognized tax benefits excluding interest and penalties	$ 0	$ 0
Accrued interest and penalties relating to unrecognized tax benefits	$ 0	$ 0

Long-Term Debt (Details Narrati

Long-Term Debt (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	Mar. 30, 2021	Feb. 23, 2021	Feb. 08, 2021	Aug. 21, 2020	Apr. 30, 2021	Apr. 30, 2020	Mar. 12, 2021	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	May 04, 2020
Debt Instrument [Line Items]
Annual principal payments								$ 1		$ 1
Additional shares issued in cancellation								(101)
Proceeds from Convertible Debt									5,022
Payments to related parties								39
Loss on Extinguishment of Debt									$ 2,500
Merger Agreement [Member]
Debt Instrument [Line Items]
Warrants to purchase common stock		143,890
Small Business Administration [Member]
Debt Instrument [Line Items]
Proceeds from Convertible Debt								10
Economic Injury Disaster Loan [Member]
Debt Instrument [Line Items]
Proceeds from Convertible Debt								$ 57
StemoniX [Member] | Merger Agreement [Member]
Debt Instrument [Line Items]
Exchnage shares issued	804,711
StemoniX [Member] | Investor [Member] | Merger Agreement [Member]
Debt Instrument [Line Items]
Warrants to purchase common stock		143,890						143,890
Warrant exercise price per share		$ 5.9059		$ 5.9059				$ 5.9059
StemoniX [Member] | Convertible Notes [Member] | Investor [Member] | Merger Agreement [Member]
Debt Instrument [Line Items]
Proceeds from Convertible Debt		$ 3,000		$ 1,250
Economic Injury Disaster Loan [Member]
Debt Instrument [Line Items]
Long-term debt								$ 57		$ 57
Debt Instrument, Interest Rate, Effective Percentage								3.75%
Debt payment terms								repayable in monthly installments starting in June 2022
2020 Convertible Notes [Member]
Debt Instrument [Line Items]
Convertible Debt							$ 10,000				$ 3,000
Proceeds from Convertible Debt							$ 5,000	$ 3,900
Debt conversion modified discount description							For any Major Investor, the modified terms provide for a fixed conversion discount on the 2020 Convertible Notes of 20% and a common stock warrant equal to 20% of the amount invested in all 2020 Convertible Notes by such Major Investor divided by the weighted average share price of the Common Stock over the five trading days prior to the closing of the Merger
2020 Convertible Notes [Member] | Merger Agreement [Member]
Debt Instrument [Line Items]
Outstanding principal amount				12,700
Accrued Interest				$ 468
Exchnage shares issued				3,338,944
Debt, Weighted Average Interest Rate									18.22%
2020 Convertible Notes [Member] | StemoniX [Member]
Debt Instrument [Line Items]
Payments to related parties							$ 3,900
2020 Convertible Notes [Member] | Series B Preferred Stock [Member]
Debt Instrument [Line Items]
Additional shares issued in cancellation			$ 3,900
2020 Convertible Notes [Member] | Series B Preferred Stock [Member] | StemoniX [Member]
Debt Instrument [Line Items]
Minimum preferred stock percentage							5.00%
2020 Convertible Notes [Member] | Maximum [Member]
Debt Instrument [Line Items]
Convertible Debt			$ 10,000
Paycheck Protection Program [Member]
Debt Instrument [Line Items]
Proceeds from Loans						$ 730
Paycheck Protection Program and CARES Act [Member] | Economic Injury Plan Loan [Member]
Debt Instrument [Line Items]
Debt Instrument, Decrease, Forgiveness					$ 730

Summary of All Common Stock War

Summary of All Common Stock Warrants Outstanding (Details)	3 Months Ended
	Mar. 31, 2022$ / sharesshares
Class of Warrant or Right [Line Items]
Outstanding Warrants | shares	2,292,996
2020 Convertible Note [Member]
Class of Warrant or Right [Line Items]
Exercise price | $ / shares	$ 5.91
Outstanding Warrants | shares	143,890
Warrants maturity date description	Feb. 23, 2026
2021 Offering [Member]
Class of Warrant or Right [Line Items]
Exercise price | $ / shares	$ 3.50
Outstanding Warrants | shares	1,624,140
Warrants maturity date description	Feb 10, 2026 - Aug 3, 2026
Advisory Fees [Member]
Class of Warrant or Right [Line Items]
Outstanding Warrants | shares	492,894
Warrants maturity date description	Jan 9, 2024 - Oct 28, 2025
Advisory Fees [Member] | Minimum [Member]
Class of Warrant or Right [Line Items]
Exercise price | $ / shares	$ 2.42
Advisory Fees [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Exercise price | $ / shares	7.59
Debt One [Member]
Class of Warrant or Right [Line Items]
Exercise price | $ / shares	$ 27.60
Outstanding Warrants | shares	14,775
Warrants maturity date description	Mar. 22, 2024
Debt Two [Member]
Class of Warrant or Right [Line Items]
Exercise price | $ / shares	$ 450
Outstanding Warrants | shares	9,185
Warrants maturity date description	Oct 17, 2022 - Dec 7, 2022
Debt Three [Member]
Class of Warrant or Right [Line Items]
Exercise price | $ / shares	$ 300
Outstanding Warrants | shares	8,112
Warrants maturity date description	Oct. 17, 2022

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	Mar. 28, 2022	Mar. 15, 2021	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2020	Feb. 23, 2021
Class of Stock [Line Items]
Fair Value Adjustment of Warrants				$ (214)
Warrant and rights issued			2,157,686
Warrants and rights outstanding			2,292,996
Cancer Genetics Inc Merger [Member]
Class of Stock [Line Items]
Warrants and rights outstanding			2,149,106
Preferred Stock Warrants [Member]
Class of Stock [Line Items]
Conversion of warrants into stock			43,107
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Outstanding					4,611,587
Shares exchanged for common stock					5,973,509
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Outstanding					3,489,470
Shares exchanged for common stock					4,524,171
Series C Preferred Stock [Member]
Class of Stock [Line Items]
Payments of Stock Issuance Costs				$ 214
Shares exchanged for common stock			699,395
Stock Issued During Period, Value, Conversion of Convertible Securities		$ 2,000
Lincoln Park Capital Fund LLC [Member]
Class of Stock [Line Items]
Payments of Stock Issuance Costs			$ 101
Purchase Agreement [Member] | Lincoln Park Capital Fund LLC [Member]
Class of Stock [Line Items]
Issuance of Incremental shares to StemoniX shareholders upon Merger, shares	405,953
Agreement description	Under the Purchase Agreement, the Company may from time to time for 30 months following May 9, 2022 (the “Commencement Date”), at its discretion, direct Lincoln Park to purchase on any single business day, or a Regular Purchase, up to (i) 50,000 common shares, (ii) 75,000 common shares if the closing sale price of its common shares is not below $1.50 per share on Nasdaq or (iii) 100,000 common shares if the closing sale price of its common shares is not below $2.50 per share on Nasdaq.
Purchase Agreement [Member] | Lincoln Park Capital Fund LLC [Member] | Maximum [Member]
Class of Stock [Line Items]
Sale of Stock, Consideration Received on Transaction	$ 15,000
Merger Agreement [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						143,890
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 5.9059
Fair Value Adjustment of Warrants			214
Merger Agreement [Member] | Investor Warrant [Member]
Class of Stock [Line Items]
Fair Value Adjustment of Warrants			$ 421

Schedule of Changes in Fair Val

Schedule of Changes in Fair Value of Level 3 Valued Instruments (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Additions		$ (250)
2020 Convertible Note [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Beginning Balance
Additions		3,746
Measurement adjustments		4
Settlement		(3,750)
Ending Balance
Warrants [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Beginning Balance
Additions		635
Measurement adjustments		(214)
Settlement		(421)
Ending Balance
Embedded Derivative [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Beginning Balance		1,690
Additions		325
Measurement adjustments		250
Settlement		(2,265)
Ending Balance
vivoPharm Business [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Beginning Balance	11,000
Additions
Measurement adjustments	(4,500)
Settlement
Ending Balance	$ 6,500

Fair Value Measurements (Detail

Fair Value Measurements (Details Narrative) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2022USD ($)$ / shares	Dec. 31, 2021USD ($)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement adjustment	$ 4.5
Estimated fair value amount	6.5	$ 11
Impairment charge	4.3
Net of estimated disposal costs	$ 4.9	$ 9.2
2020 Convertible Notes [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, term	5 years
2020 Convertible Notes [Member] | Measurement Input, Exercise Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants exercise price per share | $ / shares	$ 2.01
2020 Convertible Notes [Member] | Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	0.59
2020 Convertible Notes [Member] | Measurement Input, Price Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	86
2020 Convertible Notes [Member] | Series B Convertible Preferred Stock [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt conversion and discount description	The instrument provided the holder the right to convert the instrument into shares of Series B Preferred Stock at a 20% discount. Given the timing of the issuance of the instrument near the Merger date, management determined that there was a 99.5% probability of the holders converting the instrument to Company shares at a 20% discount
2020 Convertible Notes [Member] | Investor [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Investment in debt	$ 3

Schedule of Reconciliation of N

Schedule of Reconciliation of Numerator and Denominator for Basic and Diluted Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Earnings Per Share [Abstract]
Net loss from continuing operations	$ (4,406)	$ (7,358)
Net loss from discontinuing operations	(4,757)	(8)
Net loss	$ (9,163)	$ (7,366)
Basic and diluted weighted average shares outstanding	29,012,536	3,184,106
Basic and diluted net loss per share:
Continuing operations	$ (0.15)	$ (2.31)
Discontinuing operations	(0.17)
Net loss	$ (0.32)	$ (2.31)

Schedule of Computation of Dilu

Schedule of Computation of Diluted Shares Outstanding (Details) - shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	5,059,612	4,570,119
Common Stock Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	2,292,996	2,301,576
Common Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	2,766,616	2,268,543

Schedule of Assumptions for Sto

Schedule of Assumptions for Stock Option Grants (Details)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Valuation assumptions	0.00%	0.00%
Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected dividend yield	56.30%	119.00%
Expected term years simplified method	3 years	5 years 6 months
Risk-free interest rate	1.74%	0.98%
Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected dividend yield	69.80%	123.00%
Expected term years simplified method	6 years 1 month 6 days	6 years
Risk-free interest rate	2.13%	1.12%

Schedule of Share Option Activi

Schedule of Share Option Activity (Details) - $ / shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share-Based Payment Arrangement [Abstract]
Number of Options, Beginning Balance	2,320,097	756,383
Weighted average exercise price, Beginning Balance	$ 4.19	$ 1.82
Weighted average remaining contractual term, Beginning Balance	7 years 4 months 24 days	8 years 8 months 12 days
Number of Options, Granted	725,301	1,229,590
Weighted average exercise price, Granted	$ 1.01	$ 4.61
Number of Options, Additional options grant StemoniX holders		292,995
Weighted average exercise price, Additional options grant StemoniX holders		$ 4.61
Number of Options, assumed in Merger		55,840
Weighted average exercise price, Options assumed in Merger		$ 45.95
Number of Options, Exercised	(5,174)	(29,916)
Weighted average exercise price, Exercised	$ 0.96	$ 1.24
Number of Options, Forfeited	(255,766)	(29,349)
Weighted average exercise price, Forfeited	$ 4.22	$ 2
Number of Options, Expired	(17,842)	(7,000)
Weighted average exercise price, Expired	$ 57.24	$ 1.39
Number of Options, Ending Balance	2,766,616	2,268,543
Weighted average exercise price, Ending Balance	$ 3.01	$ 4.79
Weighted average remaining contractual term, Ending Balance	8 years 8 months 12 days	8 years 1 month 6 days
Number of Options, Exercisable	1,011,626
Weighted average exercise price, Exercisable	$ 3.72
Weighted average remaining contractual term, Exercisable	7 years 7 months 6 days

Schedule of Share Based Compens

Schedule of Share Based Compensation Activity (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total	$ 278	$ 366
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total	258	366
Shares Issued For Services [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total	$ 20

Stock-Based Compensation (Detai

Stock-Based Compensation (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	Mar. 30, 2021	Mar. 31, 2022	Mar. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
option exercisable term		7 years 7 months 6 days
Additional shares available for grant		2,228,537
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		725,301	1,229,590
Weighted average grant-date fair value of options		$ 0.54	$ 3.89
Aggregate intrinsic value		$ 100
Intrinsic value of options exercisable		100
Iintrinsic value of options exercised		1	$ 23
Unrecognized compensation cost		$ 3,500
Share-based payment arrangement, nonvested award, weighted average period		2 years 9 months
Frozen Stock Option Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
option exercisable term		10 years
2021 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting percentage	25.00%
2021 Equity Incentive Plan [Member] | Officers Key Employees and NonEmployee Consultants [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Additional shares available for grant		4,500,000
2021 Equity Incentive Plan [Member] | Officers and Other Employees [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	1,151,500	725,301
2021 Equity Incentive Plan [Member] | Independent Board Members [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	78,090
2021 Equity Incentive Plan [Member] | Board of Directors Chairman [Member] | Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares other than option granted	8,676	350,896
2021 Equity Incentive Plan [Member] | Officers and Employees [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		606,720

Schedule of Customers Represent

Schedule of Customers Representing Revenues (Details) - Revenue Benchmark [Member] - Customer Concentration Risk [Member]	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Customer A [Member]
Revenue, Major Customer [Line Items]
Concentration Risk, Percentage	27.00%	24.00%
Customer B [Member]
Revenue, Major Customer [Line Items]
Concentration Risk, Percentage	24.00%	28.00%
Customer C [Member]
Revenue, Major Customer [Line Items]
Concentration Risk, Percentage	14.00%
Customer D [Member]
Revenue, Major Customer [Line Items]
Concentration Risk, Percentage	11.00%
Customer E [Member]
Revenue, Major Customer [Line Items]
Concentration Risk, Percentage		17.00%

Segment Information (Details Na

Segment Information (Details Narrative) - Revenue Benchmark [Member]	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Customer Concentration Risk [Member] | Four Customer [Member]
Revenue, Major Customer [Line Items]
Concentration Risk, Percentage	76.00%	69.00%
Geographic Concentration Risk [Member] | Outside of United States [Member]
Revenue, Major Customer [Line Items]
Concentration Risk, Percentage	33.00%	38.00%

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	2 Months Ended	3 Months Ended
	Mar. 12, 2021	Mar. 31, 2022	Mar. 31, 2021	Feb. 23, 2021	Aug. 21, 2020
Related Party Transaction [Line Items]
Proceeds from sale of convertible note			$ 5,022
Payments to third-party		$ 39
Merger Agreement [Member]
Related Party Transaction [Line Items]
Warrants to purchase common stock				143,890
StemoniX [Member] | Investor [Member] | Merger Agreement [Member]
Related Party Transaction [Line Items]
Warrants to purchase common stock		143,890		143,890
Warrants exercise price		$ 5.9059		$ 5.9059	$ 5.9059
2020 Convertible Notes [Member]
Related Party Transaction [Line Items]
Proceeds from sale of convertible note	$ 5,000	$ 3,900

Subsequent Event (Details Narra

Subsequent Event (Details Narrative) - Sales Agreement [Member] - Canaccord Genuity LLC [Member] - Subsequent Event [Member]	Apr. 08, 2022USD ($)
Subsequent Event [Line Items]
Commission percentage	3.00%
Fees and disbursements	$ 75,000
Maximum [Member]
Subsequent Event [Line Items]
Aggregate offering price	$ 20,000,000